Skip to main content

Table 6 Subgroup analysis of heterogeneity sources in gastric cancer staging diagnostic accuracy

From: Comparison of the diagnostic accuracy of enhanced-CT and double contrast-enhanced ultrasound for preoperative T-staging of gastric cancer: a meta-analysis

Analysis

No. of models

Pooled SE(95% CI)

I2(%)

P1

Pooled SP(95% CI)

I2(%)

P2

Pooled PLR(95% CI)

I2(%)

P3

Pooled NLR(95% CI)

I2(%)

P4

AUC

T1

 Geographical Regions

Asian

24

0.58 (0.47–0.68)

95.42

0

0.98 (0.96–0.99)

96.56

0

27.86 (14.67–52.93)

94.44

0

0.43 (0.34–0.55)

97.21

0

0.91

European and African

4

0.44 (0.15–0.79)

76.09

0.01

0.97 (0.90–0.99)

72.81

0.01

17.48(5.77–52.92)

0

0.71

0.57(0.3–1.1)

58.79

0.06

0.93

 CTs with varying slice numbers

≥ 64

9

0.56 (0.39–0.71)

89.68

0

0.97 (0.94–0.98)

71.85

0

17.87 (8.05–39.66)

65.8

0

0.46 (0.31–0.67)

93.28

0

0.94

< 64

19

0.56 (0.44–0.68)

94.22

0

0.98 (0.96–0.99)

96.93

0

32.75 (16.00–67.04)

94.79

0

0.45 (0.34–0.58)

96.86

0

0.91

 Sample size

≥ 100

12

0.52(0.36–0.67)

97.58

0

0.98 (0.95–0.99)

98

0

25.65(11.26–58.45)

96.29

0

0.49(0.36–0.67)

98.43

0

0.9

< 100

16

0.61(0.48–0.73)

47.28

0.02

0.98 (0.95–0.99)

59.97

0

25.42(11.47–56.35)

2.22

0.06

0.40(0.28–0.56)

70.01

0

0.93

 Types of Study Design

prospective

10

0.53(0.42–0.63)

48.25

0.04

0.98(0.95–0.99)

80.29

0

35.14(12.91–95.66)

41.15

0

0.48(0.38–0.61)

54.89

0.02

0.83

retrospective

18

0.57(0.43–0.70)

97.1

0

0.97 (0.95–0.99)

96.19

0

21.58(11.09–41.97)

93.91

0

0.44(0.32–0.61)

98.5

0

0.92

T2

 Geographical Regions

Asian

25

0.62 (0.53–0.70)

85.46

0

0.90(0.87–0.92)

80.17

0

5.95(4.77–7.43)

72.61

0

0.43 (0.34–0.54)

89.41

0

0.88

European and African

6

0.66 (0.44–0.83)

69.27

0.01

0.80(0.74–0.85)

39.1

0.15

3.28(2.04–5.28)

0

0.15

0.42 (0.22–0.80)

86.4

0

0.81

 CTs with varying slice numbers

≥ 64

9

0.65(0.50–0.77)

71.61

0

0.92(0.88–0.94)

69.98

0

7.68(5.61–10.51)

0

0.58

0.39(0.37–0.56)

73.82

0

0.9

< 64

22

0.62 (0.52–0.72)

87.05

0

0.87(0.83–0.89)

82.98

0

4.66(3.66–5.91)

69.57

0

0.43 (0.34–0.56)

89.59

0

0.86

 Sample size

≥ 100

12

0.54(0.43–0.64)

89.41

0

0.91(0.89–0.93)

84.16

0

6.17(4.62–8.22)

80.76

0

0.51(0.40–0.64)

92.47

0

0.89

< 100

19

0.71(0.61–0.79)

52.69

0

0.85(0.80–0.88)

55.82

0

4.66(3.47–6.25)

9.32

0.03

0.35(0.25–0.48)

77.21

0

0.86

 Types of Study Design

prospective

10

0.71(0.61–0.79)

60.9

0.01

0.87(0.82–0.91)

80.85

0

5.55(4.18–7.37)

41.94

0

0.33(0.25–0.44)

42.93

0.07

0.87

retrospective

21

0.58 (0.47–0.68)

85.25

0

0.89(0.85–0.92)

84.28

0

5.20(3.87–6.99)

69.34

0

0.47(0.37–0.61)

87.77

0

0.86

T3

 Geographical Regions

Asian

25

0.79 (0.73–0.84)

87.43

0

0.84(0.87–0.81)

73.88

0

5.03(4.26–5.95)

58.26

0

0.25(0.20–0.31)

89.45

0

0.89

European and African

6

0.69 (0.56–0.80)

72.39

0

0.81(0.67–0.90)

80.6

0

3.66(1.73–7.74)

77.04

0

0.38(0.23–0.63)

82.33

0

0.81

 CTs with varying slice numbers

≥ 64

9

0.79 (0.70–0.86)

66.47

0

0.85(0.81–0.89)

46.53

0.06

5.35(3.94–7.28)

43.76

0

0.25(0.17–0.37)

73.72

0

0.89

< 64

22

0.77 (0.70–0.82)

89.2

0

0.83(0.79–0.87)

79.55

0

4.66(3.7–5.86)

67.91

0

0.28(0.21–0.36)

90.32

0

0.88

 Sample size

≥ 100

12

0.82(0.75–0.87)

93.59

0

0.83(0.80–0.86)

83.12

0

4.86(4.06–5.82)

73.1

0

0.22(0.16–0.30)

94.95

0

0.89

< 100

19

0.72 (0.65–0.78)

52.02

0

0.86(0.80–0.89)

70.26

0

5.07(3.47–7.40)

62.12

0

0.32(0.25–0.41)

63.14

0

0.85

 Types of Study Design

prospective

10

0.82(0.77–0.87)

52.07

0.03

0.87(0.79–0.92)

63.88

0

6.14(4.03–9.35)

25.41

0.01

0.20(0.16–0.26)

53.99

0.02

0.9

retrospective

21

0.76(0.69–0.82)

88.42

0

0.84(0.80–0.87)

79.65

0

4.67(3.68–5.93)

73.88

0

0.29(0.22–0.38)

88.95

0

0.87

T4

 Geographical Regions

Asian

24

0.77(0.71–0.83)

66.9

0

0.96(0.95–0.97)

74.52

0

20.32(14.37–28.73)

52.07

0

0.24(0.18–0.31)

77.44

0

0.95

European and African

6

0.78(0.44–0.94)

83.86

0

0.95(0.89–0.98)

81.45

0

15.32(5.91–39.72)

67.75

0

0.24(0.07–0.75)

91.17

0

0.96

 CTs with varying slice numbers

≥ 64

8

0.73(0.55–0.86)

74.76

0

0.95(0.89–0.97)

74.74

0

13.39(7.50–23.91)

23.36

0.02

0.28(0.16–0.49)

88.17

0

0.94

< 64

22

0.77(0.69–0.74)

74.01

0

0.96(0.95–0.98)

74

0

21.41(14.43–31.78)

55.17

0

0.24(0.17–0.33)

82.74

0

0.97

 Sample size

≥ 100

12

0.80(0.72–0.86)

76.78

0

0.96(0.95–0.98)

80.03

0

22.62(14.94–34.25)

62.33

0

0.21(0.15–0.29)

85.32

0

0.96

< 100

18

0.74(0.61–0.83)

65.6

0

0.95(0.92–0.97)

66.95

0

15.62(9.25–26.39)

40.88

0

0.28(0.18–0.43)

78.17

0

0.95

 Types of Study Design

prospective

10

0.77(0.64–0.86)

73.93

0

0.96(0.95–0.97)

0

0.74

20.41(14.18–29.37)

80.56

0

0.24(0.15–0.39)

80.56

0

0.97

retrospective

20

0.77(0.68–0.84)

73.2

0

0.96(0.93–0.97)

83.23

0

15.7(11.16–28.29)

70.8

0

0.24(0.17–0.34)

85.17

0

0.95

  1. P1-P4 represent the P values for assessing the overall heterogeneity in each subgroup through the Cochran Q test
  2. TP true positives, FN false negatives, TN true negatives, FP false positives, CT Computed Tomography, SROC summary receiver operating characteristic